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Abstract
Lysine-specific demethylase 6A (KDM6A) and members of the Switch/Sucrose Non-Fermentable (SWI/SNF) family are
known to counteract the activity of Enhancer of Zeste Homolog 2 (EZH2), which is often overexpressed and is associated
with poor prognosis in muscle-invasive bladder cancer. Here we provide evidence that alterations in chromatin modifying
enzymes, including KDM6A and members of the SWI/SNF complex, are frequent in muscle-invasive bladder cancer. We
exploit the loss of function mutations in KDM6A and SWI/SNF complex to make bladder cancer cells susceptible to EZH2-
based epigenetic therapy that activates an immune response to drive tumor cell differentiation and death. We reveal a novel
mechanism of action of EZH2 inhibition, alone and in combination with cisplatin, which induces immune signaling with the
largest changes observed in interferon gamma (IFN-γ). This upregulation is a result of activated natural killer (NK) signaling
as demonstrated by the increase in NK cell-associated genes MIP-1α, ICAM1, ICAM2, and CD86 in xenografts treated with
EZH2 inhibitors. Conversely, EZH2 inhibition results in decreased expression of pluripotency markers, ALDH2 and CK5,
and increased cell death. Our results reveal a novel sensitivity of muscle-invasive bladder cancer cells with KMD6A and
SWI/SNF mutations to EZH2 inhibition alone and in combination with cisplatin. This sensitivity is mediated through
increased NK cell-related signaling resulting in tumor cell differentiation and cell death.
Introduction
The tumor suppressor Switch/Sucrose Non-Fermentable
(SWI/SNF) complex [1–3] and Polycomb Repressive
Complex (PRC2), of which the oncogene Enhancer of
Zeste Homologue 2 (EZH2) [4–6] is the catalytic com-
ponent, have opposing roles in regulation of gene tran-
scription [7]. SWI/SNF family members displace PRC2
on target gene loci to allow gene transcription [8, 9].
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Malignant rhabdoid and ovarian tumors with SWI/SNF
family member mutations are believed to be dependent on
EZH2 activity and thus more sensitive to EZH2 inhibition
[10–15]. EZH2 function is also antagonized by Lysine-
specific Demethylase 6A (KDM6A) to activate gene
transcription of E-cadherin, cell cycle regulators, tumor
suppressor STF amongst others [16–18]. KDM6A
removes trimethylation marks from histone 3 lysine 27
(H3K27) [19] and its catalytic JmjC domain is essential
for histone demethylase function [20, 21].
Similar to rhabdoid and ovarian tumors with SWI/SNF
mutations [10–15], complete loss of KDM6A protein
sensitizes bladder cancer cell lines and patient-derived
xenografts to EZH2 inhibition [22]. EZH2 sensitivity is
attributed to IGFBP3 upregulation in KDM6A-null cells,
but not in wild-type KDM6A cells [22]. This EZH2 sen-
sitivity in bladder cancer is based on total loss of KDM6A
protein. In muscle-invasive bladder cancer (MIBC),
KDM6A and members of the SWI/SNF family members
are frequently mutated [23, 24], while EZH2 is over-
expressed in tumors compared to adjacent non-tumor
areas [25, 26]. EZH2 inhibition in the context of SWI/
SNF family member and/or KDM6A mutations, but not
necessarily at protein level alterations, in MIBC is
unexplored.
Here we show that EZH2 inhibition is most effective in
bladder cancer cells with both SWI/SNF family member
and KDM6A mutations, and is capable of augmenting cis-
platin response. We show for the first time that EZH2
inhibition in HT1376 xenografts with KDM6A and SWI/
SNF family member mutations activates a natural killer
(NK) cell-based immune response. NK cell activity was
detected by IFN-γ upregulation and increased protein levels
of Neural Cell Adhesion Marker (NCAM/CD56) and Nat-
ural Cytotoxicity triggering Receptor 1 (NCR1). Our results
indicate that EZH2 inhibition alone and in combination with
cisplatin boosts NK cell response to drive tumor differ-
entiation and death in bladder cancer cells and xenografts.
Therefore, we conclude that epigenetic therapy targeting
EZH2 alone or in combination with cisplatin can be bene-
ficial in bladder tumors with KDM6A and/or SWI/SNF
mutations and/or increased EZH2 activity.
Materials and methods
Roswell Park Comprehensive Cancer Center (Roswell
Park) patient cohort
Tumor samples from patients with MIBC and with
informed consent were collected at the time of radical
cystectomy at Roswell Park. RNA and exome sequencing
of de-identified tumors were conducted.
Cell culture
HT1376, T24, and UM-UC-3 cells were obtained from
ATCC, and cultured in MEM, McCoy’s, and DMEM
media, respectively, supplemented with 10% fetal bovine
serum, and penicillin/streptomycin. Overall, 10 mM
EPZ011989 stock solution was thawed no more than four
times from −20 °C and diluted in media for treating cells at
1 µM concentration. In vitro treatments lasted 13 days.
Initial treatment of cells with EPZ011989 occurred on days
1 and 4. Cells were harvested and re-plated at day 7 fol-
lowed by additional EPZ011989 treatment on day 8. 1.0
mg/mL cisplatin was diluted to 0.25 µg/mL in media for
treatment on day 11. On day 13, cells were harvested for
western blots, clonogenic, and cell cycle assays. For
siEZH2 experiments, cells were treated with 50 nM siRNA
(Dharmacon, L-004218-00-0005) for 96 h.
Western blots
Cells were trypsinized for histone extraction as per the
Abcam protocol. Additionally, cells were lysed using RIPA
buffer for whole-cell lysates. Protein concentration was
assessed (BioRad, 5000116). A total of 10 µg total histones
and 40 µg whole-cell lysates were loaded on gels. Mem-
branes were incubated overnight at 4 °C with primary
antibody in 5% BSA in TBST. Primary antibodies used
were: H3K27me3 (Cell signaling, 9733S), total histone H3
(Cell Signaling, 9715), EZH2 (Cell signaling, 5246),
KDM6A (Atlas Antibodies, HPA002111), ALDH2
(Abcam, ab108306), and CK5 (Covance, PRB 160-P).
Membranes were incubated with HRP-conjugated second-
ary rabbit antibody (GE Life Sciences, NA934V). The
secondary antibody was detected using Luminata Cres-
cendo Western HRP Substrate (WBLUC0500). The mem-
branes were stripped with Restore Plus (Thermo Scientific,
46428) and re-probed with GAPDH (Abcam, ab9485) or
Total H3.
Clonogenic assay
50 (T24), 100 (UM-UC-3), and 200 (HT1376) cells were
plated onto 6-well plates to form clones for 9–12 days.
Plates were rinsed with PBS, stained with crystal violet for
10 mins, and rinsed again. Overnight dried clones were
counted.
Cell cycle analysis
Cells were harvested with trypsin and re-suspended in 75%
ethanol. Pellets were washed twice with PBS and re-
suspended in 50 µg/mL propidium iodide (ThermoFisher,
P3566) and 5 µg/mL ribonuclease (ThermoFisher,
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EN0531). Fortessa instrument and ModFit software were
used for cell cycle analysis.
In vivo study
The national guidelines for the use of laboratory animals
were followed. 3 × 106 HT1376 cells were injected sub-
cutaneously in the left flank of nude mice. 100-250 mm3
tumors were treated with vehicle, cisplatin (3 mg/kg, I.P,
weekly once), EPZ011989 (500 mg/kg, oral gavage, every
12 h) and combination therapy for 22 days. Body weights
were measured before treatments for dosing and toxicity.
Tumors were blindly measured twice per week. On day 22,
mice were killed, tumors were processed for RNA-
sequencing and immunohistochemistry (IHC).
RNA-sequencing
Frozen tumors were crushed, and RNAs were isolated
(ZymoResearch, R2052). Paired-end RNA-sequencing was
performed on end-point tumors with fastQC assessing the
base quality of raw reads. Tophat 2 was used to align reads
to human genome b37 from Ensembl. Raw read counts
were analyzed using R, and differentially expressed genes
between four groups were identified. Z-scores were calcu-
lated for PRC2, stem cell-like and NK cell signatures.
Boxplots were used to show the z-scores for each signature
in each sample set. Wilcoxon-paired test were used to test
the difference among the three signatures in each sample
set. Log CPM (count per million) were used to quantify the
expression of each gene and then normalized by the number
of standard deviations from the mean. The sum of the
normalized values of signature genes was calculated as the
z-score for each sample.
RNA-sequencing validation
cDNA was prepared (BioRad, 170-8891). SYBR green
(BioRad, 172-5121) was used for qPCR with primers listed
below:
Immunohistochemistry
Tumors were fixed in 10% Neutral Buffer Formalin (Sigma,
HT-501126), paraffin embedded and stained with hema-
toxylin and eosin, EZH2, H3K27me3, Ki67 (Abcam,
ab15580), ALDH2, CK5, p63, CD56 (Cell signaling, 3576),
and TUNEL (R&D, 4828-30-DK). Three scorers blindly
scored H3K27me3. All the other staining’s were analyzed
by Image J to calculate the area fraction for CK5, CD56 and
NCR1 (Abcam, ab214468) as well as percent positive
nuclei (by ImmunoRatio [27]) for Ki67, p63, and EZH2.
The staining’s were also subjected to blinded observation
by the pathologist.
Statistical analysis
GraphPad Prism was used for graphs and statistical analy-
sis. In vitro experiments were compared by student’s t-test.
For mathematical modeling, tumor volumes by treatment
and time point were reported using mean and standard
deviation and graphically represented by mean plots (mean
± standard error). Missing tumor volumes were extrapolated
using linear regression based on a given mouse’s observed
log-tumor volumes. Linear mixed was used to model log
(volume) as a function of treatment, time, their interaction,
and random mouse effect. The fitted model estimated how
long it would take a tumor at 100 mm3 to reach a volume of
1000 mm3. The association between last observed tumor
volumes and treatment groups were evaluated using one-
way ANOVA model; with pairwise comparisons made as
appropriate. H3K27me3 scores were calculated as: total
score= 1*(# cells scored 1)+ 2*(# cells scored 2)+ 3*
(# cells scored 3). The resulting H3K27me3 scores ranged
from 0 (all cells scored as 0) to 600 (all cells scored as 3).
H3K27me3 scores were modeled as a function of treatment
and random sample effect using a linear mixed model with
assumptions verified graphically. Mean H3K27me3 scores
were compared between groups using Tukey-adjusted tests
about the least square means. Time-to-event outcomes
were reported by EZH2/KDM6A status using standard
Genes Forward primer Reverse primer
IFNγ GCATCGTTTTGGGTTCTCTTG AGTTCCATTATCCGCTACATCTG
MIP-1α CGGCAGATTCCACAGAATTTC AGGTCGCTGACATATTTCTGG
CD3D GTGACCTGGCTTTATCTACTGG CACTCTGTCCTCAAGTTCCTC
CYT1 CTGGCTATTGAAACTCGGAGG CTTCCCGGATACTCAGATTCTC
CD86 ACATCTTCATGCGACAAAAGTG GGTAATGTCTTTTTGCCTTCTGG
ICAM1 CAATGTGCTATTCAAACTGCCC CAGCGTAGGGTAAGGTTCTTG
ICAM2 GATGTCCTCTTTCGGTTACAGG CCTCGAATACCTTCTCATCCG
GAPDH GTGGTCTCCTCTGACTTCAAC CCTGTTGCTGTAGCCAAATTC
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Kaplan–Meier methods; with log-rank test comparisons. All
analyses were conducted in SAS v9.4 (Cary, NC) at a
significance level of 0.05.
Results
Mutations and altered expression of chromatin
remodeling genes are recurrent in MIBC patients
Neoadjuvant cisplatin-based chemotherapy followed by
either radical cystectomy or PD-L1-based immunotherapy
are the only two options for patients with MIBC that has
spread locally or regionally. Cisplatin-treated patients often
recur while PD-L1-based therapy is only effective in 20% of
the patients [28–30]. It is therefore critical not only to
identify therapies effective in patients with cisplatin failure
but also increase the probability of targeted therapy success
based on the molecular characteristics of patient tumors. For
this purpose, we systematically analyzed bladder tumor
tissues from patients treated at Roswell Park by exome and
RNA-sequencing. 20% of Roswell Park tumors exhibited
frameshift, nonsense and missense mutations in Lysine-
specific Demethylase 6A (KDM6A), that specifically
removes methylation marks from histone 3 lysine 27
(H3K27) (Fig. 1a, Supplementary Table 1). SWI/SNF
complex family members that regulate transcription by
chromatin remodeling [31], including ACTL6B, ARID1A,
and SMARCA4, were mutated in 18% of tumors (Fig. 1a,
Supplementary Table 1). 10% of tumors had concurrent
mutations in both KDM6A and the SWI/SNF family
members. These frequencies of mutations were similar to
The Cancer Genome Atlas (TCGA) bladder cancer cohort
(Supplementary Figure 1A).
RNA-sequencing also revealed that a subset of SWI/SNF
family members and EZH2 transcripts were significantly
altered in tumors compared to non-tumor tissues (Fig. 1b).
We further categorized muscle-invasive tumors based on
their mutational status as KDM6A alone, SWI/SNF alone,
both KDM6A and SWI/SNF and neither mutation. We
analyzed genes that are repressed by Polycomb Repressive
Complex 2 [32], of which EZH2 is the catalytic subunit, in
these mutational subtypes. Tumors with KDM6A only and
KDM6A/SWI/SNF family member mutations had lower z-
scores of PRC2 targets compared to tumors with neither
mutation (Fig. 1c). This suggests that tumors with KDM6A
only and KDM6A/SWI/SNF mutations have increased
EZH2 activity and can potentially be sensitive to EZH2
targeted therapy. In TCGA, patients with either loss of
function mutations or mRNA downregulation in either
KDM6A or SWI/SNF family members had worse overall
(30.91 vs. 61.4 months) and progression-free survival
(17.35 vs. 87.48 months, p < 0.05) compared to patients
with no alterations (Supplementary Figure 1B). Patients
with EZH2 amplification and/or mRNA overexpression had
shorter overall (28.38 vs. 33.11 months) and progression-
free survival (27.83 vs. 32.59 months) compared to patients
with no alterations (Supplementary Figure 1B). We did not
have adequate patient numbers in the Roswell Park cohort
to perform survival analysis. In summary, common genetic
and transcriptome level alterations in chromatin remodeling
genes in muscle-invasive bladder tumors can provide a
framework that could be exploited for novel epigenetic-
based therapy. Combined, these data indicate that EZH2
inhibition could be a rationale therapeutic strategy for a
significant subset of MIBC.
Cells with both KDM6A and SWI/SNF mutations are
sensitive to EZH2 inhibition
The SWI/SNF complex and KDM6A oppose EZH2-
mediated transcriptional repression [7, 19]. Tumors with
either SWI/SNF or KDM6A mutations are thought to be
sensitive to EZH2 inhibition [13, 22, 33]. Therefore, we
investigated whether EZH2 inhibition differentially affects
bladder cancer cell lines with mutations in either KDM6A
alone or both KDM6A and SWI/SNF family members. In
our studies, we used: (1) HT1376 (KDM6A and SWI/SNF
family mutations), (2) T24 (KDM6A nonsense mutation)
and, (3) UM-UC-3 (KDM6A and SMARCA4 mutations)
(Supplementary Table 2 [34]). First, we confirmed the
activity of the EZH2 inhibitor, EPZ011989, by testing
H3K27me3 protein levels after 4 days of treatment.
H3K27me3 levels were reduced to similar levels in HT1376
and UM-UC-3 cells treated with 0.01 µM EPZ011989 as
T24 cells treated with 1 µM EPZ011989 (Supplementary
Figure 2A). Therefore, we used 1 µM EPZ011989 to ensure
H3K27me3 reduction in all three cell lines. We also tested
H3K27me3 levels in short-term cisplatin-treated cells,
since cisplatin is the first-line therapy for MIBC patients.
0.25 µg/mL of cisplatin, a sub-toxic cisplatin concentration
[35], increased H3K27me3 levels in all three cell lines
(Supplementary Figure 2B). Cisplatin-mediated H3K27me3
alterations prompted us to test the effects of EPZ011989
alone and in combination with cisplatin on cell prolifera-
tion, cell cycle and clonogenicity in vitro. EPZ011989 alone
and in combination with cisplatin significantly reduced cell
proliferation, caused G2/M arrest and reduced clonogenicity
of HT1376 cells (Fig. 2a–c, Supplementary Table 3). In T24
and UM-UC-3 cells, EPZ011989 alone and in combination
with cisplatin inhibited cell proliferation, but only the
combination caused significant G2/M arrest and reduced
clonogenicity compared to vehicle and single agent treat-
ments (Fig. 2a–c, Supplementary Table 3). The G2/M arrest
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Fig. 1 Mutations in KDM6A and SWI/SNF complex genes are com-
mon in muscle-invasive bladder cancer. a Exome-sequencing analysis
of 138 bladder tumor patients from Roswell Park Comprehensive
Cancer Center (Roswell Park) revealed mutations in several chromatin
remodeling enzymes. KMD6A, a histone demethylase, responsible for
removing trimethylation mark on H3K27 is mutated in 20% while
SWI/SNF complex family members are mutated in 18% of tumors.
Mutations include missense and nonsense mutations as well as fra-
meshift deletions, insertions and in frame deletions. b RNA-
sequencing of a 66 tumors revealed significant alterations in gene
expression of EZH2 and members of the SWI/SNF complex. c z-scores
of PRC2-regulated genes were lower in tumors with KDM6A and
KDM6A/SWI/SNF mutations compared to tumors without any
mutations or SWI/SNF mutations alone
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Fig. 2 Bladder cancer cells with ARID1A and/or SWI-SNF mutations
are sensitive to EZH2 inhibition. a 1 µM EPZ011989 alone or in
combination with 0.25 µg/ml cisplatin reduced the number of viable
cells compared to vehicle. The Y-axis represents the percentage of cells
normalized to the vehicle, and the X-axis represents the cell lines used
in the study. b EPZ011989 alone or in combination with cisplatin
increased the number of cells in the G2/M phase of the cell cycle. The
Y-axis represents the percentage of propidium iodide positive cells,
and the X-axis represents the different phases of the cell cycle. c The
image is a representative of clonogenic assay performed on all three
cell lines. EPZ011989 alone or in combination with cisplatin sig-
nificantly reduced the number of clones. The Y-axis represents the
surviving fraction of clones normalized to the vehicle. Error bars
represent standard error of means from technical duplicates and bio-
logical triplicates. Students t-test was used to analyze significance
between the single agent and combination treatments. *p < 0.05, **p <
0.01, ***p < 0.001, triangle indicates significant difference compared
to vehicle, hash indicates a significant difference between the
EPZ011989 and cisplatin alone treatments
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in cisplatin-treated cells did not correspond to reduced cell
proliferation (Fig. 2a, b). It is worth noting that we used
sub-toxic doses of cisplatin [35] that may not robustly
reduce cell proliferation in these cells. T24 and UM-UC-3
cell lines were more sensitive to cisplatin in the clonogenic
assay than the cell proliferation assay. We think that the
cisplatin concentration used in our study reduces the long-
term ability of cells to form individual clones, but does not
affect short-term (48 h) proliferation. In summary, our
in vitro assays suggest that HT1376 cells with both
KDM6A and multiple SWI/SNF family member mutations
are more sensitive to EZH2 inhibition alone compared to
T24 and UM-UC-3 cells.
Next, we used HT1376-derived xenografts to determine
whether sensitivity to EZH2 inhibition in vitro is maintained
in vivo. Similar to observations in vitro, EPZ011989 and
combination treatments reduced HT1376 xenograft growth
compared to vehicle and cisplatin-treated mice (Fig. 3a,
Supplementary Table 4) without causing significant body
weight loss (Supplementary Figure 3A–E). To determine
the long-term effect on xenograft growth, we used mathe-
matical modeling to calculate the rate of tumor growth to a
predetermined end-point volume, 1000 mm3. The model
predicted that xenografts from vehicle, cisplatin, and
EPZ011989 would reach a volume of 1000 mm3 in 58.5,
77.7, and 399.8 days, respectively, but the combination
would prevent xenografts from reaching 1000 mm3
(Fig. 3b). Additionally, EPZ011989 and combination-
treated xenografts were predicted to shrink compared to
vehicle and cisplatin groups. At the end of the study,
EPZ011989 (0.258+ 0.054 g) and combination (0.123 ±
0.027 g)-treated xenografts were significantly smaller than
vehicle (0.373 ± 0.093 g) and cisplatin (0.219 ± 0.079 g)-
treated tumors (Fig. 3c, Supplementary Table 4). Corre-
spondingly, EPZ011989 and combination-treated xeno-
grafts had reduced Ki67 staining, a cell proliferation
marker, compared to vehicle and cisplatin-treated xeno-
grafts (Fig. 4a, b, Supplementary Table 4). To analyze
whether reduced proliferation was due to increased cell
death in treatment groups, we performed TUNEL staining, a
marker of cell death, on tumor sections. We found greater
TUNEL positivity in EPZ011989, cisplatin and
combination-treated xenografts (Fig. 4a). Finally, we con-
firmed EPZ011989 activity in vivo by quantitating
H3K27me3 staining by immunohistochemistry.
H3K27me3 scores were significantly lower in EPZ011989
(168.5 ± 39.7) and combination (110 ± 37.7)-treated xeno-
grafts compared to vehicle (364.2 ± 45.0) and cisplatin
(430.4 ± 39.7)-treated xenografts without obvious changes
in EZH2 protein expression (Fig. 4a, b, Supplementary
Table 4). In summary, HT1376-derived xenografts maintain
sensitivity to EZH2 inhibition alone and in combination
with cisplatin in vivo.
Transcripts associated with NK cell activity are
elevated with EZH2 inhibition
To understand the potential molecular mechanism of EZH2
inhibition-mediated anti-tumor activity in our studies, we
used an unbiased RNA-sequencing approach. We per-
formed RNA-sequencing on HT1376 and T24 cells treated
2106 S. Ramakrishnan et al.
for 4 days with EPZ011989 and HT1376 xenografts. We
focused on upregulated transcripts as these are more likely
to be the direct result of increased gene transcription due to
decreased H3K27me3 by EZH2 inhibition. IFN-γ RNA
transcripts had the highest fold change in EPZ011989 and
combination-treated HT1376 xenografts (Supplementary
Table 5). Transcripts associated with IFN-γ signaling were
significantly enriched only in those xenografts treated with
EPZ011989, and not in vehicle or cisplatin-treated mice
(Fig. 5a). IFN-γ is one of the downstream effectors of
activated NK cells, and it is important to note that athymic
nude mice still have active NK, B, and dendritic cells.
Using qPCR, we validated upregulation of a set of tran-
scripts associated with NK cell activity, including IFN-γ,
CYTH1, CD86, ICAM1, ICAM2, MIP-1α, and CD3D in
EPZ011989 and combination-treated xenografts (Fig. 5a).
Interestingly, we found a large number of immune asso-
ciated transcripts in short-term EPZ011989-treated HT1376
and T24 cells in vitro (Supplementary Figure 4A–D, Sup-
plementary Table 6–9). This suggests that EZH2 inhibition
alters expression of immune signaling transcripts in tumor
cells in vitro, and in vivo in presence of a limited immune
microenvironment.
To evaluate whether transcript level changes in NK cell-
associated signaling increased infiltrating lymphocytes in
EPZ011989-treated xenografts, we used CD56 also known
as Neural Cell Adhesion Molecule 1 (NCAM1) and NCR1
(Natural Cytotoxicity triggering Receptor 1) as markers of
NK cells [36]. CD56 staining was significantly higher in
combination-treated xenografts compared with vehicle,
cisplatin and EPZ011989-treated mice (Fig. 5b, c, Supple-
mentary Table 4). Similarly, NCR1 was significantly higher
in EPZ011989 and combination-treated tumors compared to
vehicle and cisplatin-treated groups (Fig. 5b, c, Supple-
mentary Table 4). NK cells are known to mediate tumor cell
lysis [37] and we observed association of increased NK cell
infiltration with increased TUNEL staining in EZH2
inhibitor-treated xenografts. Overall, these results suggest
that EPZ011989 alone and in combination with cisplatin
can increase NK cell infiltration and thereby tumor cell
cytotoxicity in HT1376 xenografts.
To determine whether NK cells have any MIBC clinical
relevance, we examined transcript levels of NK cell ligands
and receptors in patient tumors. NK cell-associated tran-
scripts, both ligands and receptors, were consistently
downregulated in the Roswell Park cohort (Fig. 5d) with the
exception of ULBP1, an NK cell ligand. Although ULBP1
ligand is upregulated, the NKG2D receptor to which it
binds is downregulated. Analyses of these genes in our
Roswell Park cohort revealed that tumors with either
KDM6A, SWI/SNF or both mutations had lower insignif-
icant z-scores compared with tumors with neither mutation
(Fig. 5e). The lower expression of NK cell ligands and
receptors suggests that NK cells have reduced activity in
bladder tumors with KDM6A and/or SWI/SNF mutations.
Upregulation in any one of the NK cell ligands or receptor
transcripts was associated with better overall and
progression-free survival compared to tumors with no
alterations in TCGA (Supplementary Figure 5A–B). Over-
all, these data indicate that activation of NK cells is one of
the potential anti-tumor mechanisms in EZH2 inhibitor-
treated HT1376 xenografts with KDM6A and SWI/SNF
family member mutations.
EZH2 inhibition-mediated NK cell activity is
associated with reduced markers of pluripotency
EZH2 maintains stem-like features in cancer [38, 39], while
cisplatin-based chemotherapy can enrich for stem-like cells
leading to chemo-resistance [40, 41]. In addition, NK cell-
mediated tumor differentiation can sensitize tumor cells to
chemotherapy [36, 42]. Therefore, we tested the con-
sequences of EPZ011989 and cisplatin treatment on
pluripotency-associated markers both in vitro and in vivo. In
vitro, we measured two markers: (1) CK5 that gives rise to
muscle-invasive lesions in mice with BBN-induced bladder
cancer [43], and (2) ALDH2 as an indicator of pluripotent
potential [36]. Short-term EPZ011989 or siEZH2 treatment
reduced CK5 expression in HT1376 and T24 cells
and ALDH2 expression in T24 cells (Supplementary
Figure 6A-D). CK5 was absent in UM-UC-3 cells, while
HT1376 cells did not express ALDH2. ALDH2 expression
remained unaltered in either EPZ011989 or siEZH2-treated
UM-UC-3 cells (Supplementary Figure 6A–D). Cisplatin
treatment increased ALDH2 expression in UM-UC-3 cells
Fig. 3 HT1376 xenografts with KDM6A and ARID1A mutations are
sensitive to EZH2 inhibition alone and in combination with cisplatin.
a 500 mg/kg EPZ011989 alone or in combination with 3 mg/ml cis-
platin reduced HT1376 tumor volume in nude mice. The Y-axis
represents tumor volume in mm3 and the X-axis represents number of
days in the study. There is a significant difference in the tumor growth
rate between the combination treatment and cisplatin alone treatment.
b Mathematical modeling of tumor growth rate indicated that
the vehicle, Cisplatin, EPZ011989 would grow tumors from 100 to
1000 mm3 in 58.5, 77.7, and 399.8 days, respectively. The combina-
tion treatment is predicted to not reach 1000 mm3. c End-point tumor
weights showed that the combination treatment had significantly lower
tumor weight as compared cisplatin alone treatment. The Y-axis
represents the tumor weight in grams and the X-axis represents the
different groups. Error bars represent standard error of means of all the
mice in each group. One-way ANOVA model with pairwise com-
parisons made as appropriate were performed to test differences
between single and combination treatments. *p < 0.05, **p < 0.01,
***p < 0.001, triangle indicates significant difference as compared to
vehicle, hash indicates significant difference between the EPZ011989
and cisplatin alone treatments
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compared to vehicle-treated cells (Supplementary
Figure 6E). In vivo, the expression of pluripotency markers
CK5, ALDH2 and p63 were heterogeneous in all the
xenografts that we assayed. Overall, CK5 staining was sig-
nificantly lower in EPZ011989 and combination groups
compared to vehicle control animals (Fig. 6a, b). A lower
proportion of xenograft cells were positive for ALDH2 in
EPZ011989 and combination groups (Fig. 6a). However,
ALDH2 staining was more intense in infiltrating lympho-
cytes in EPZ011989 and combination-treated xenografts
(Fig. 6a). Finally, p63 staining was significantly higher
in cisplatin-treated tumors compared to vehicle group
(Fig. 6a, b). To summarize, cisplatin treatment, down-
regulation of EZH2 protein by siEZH2 and pharmacological
inhibition of EZH2 activity alter the expression of plur-
ipotency markers in a subset of tested bladder cancer cells.
To determine whether the pluripotency markers are
altered in bladder tumors and are associated with KDM6A
and/or SWI/SNF tumors, we queried our Roswell Park
genomics data. RNA transcripts that are associated with
stem-like features were elevated in the Roswell Park cohort
(Fig. 6c). In TCGA, either amplification or mRNA upre-
gulation in any of these markers was associated with worse
survival compared to patients with no alterations (Supple-
mentary Figure 7A-B). Tumors with both KDM6A and
SWI/SNF mutations had higher pluripotency z-scores
compared to tumors with either single KMD6A, single
SWI/SNF complex, or neither mutation (Fig. 6d). Higher
pluripotency z-scores were associated with lower NK cell
signature z-scores in tumors with both mutations compared
to the other mutation subtypes. In conclusion, our results
suggest that bladder cancer cells and xenografts with
KDM6A and SWI/SNF family member mutations can
benefit from EZH2 inhibition that increases NK cell activity
leading to reduction in cells with pluripotency potential
(Fig. 6e).
Discussion
Our findings support that there is clinical utility in using
EZH2 inhibitors for MIBC patients whose tumors have loss
of function mutations in KDM6A and/or SWI/SNF com-
plex. KDM6A and/or SWI/SNF family member mutations
and EZH2 amplification/overexpression seem to be
mutually exclusive in TCGA. Without KDM6A/SWI/SNF
complex to oppose EZH2 function [8, 9, 19], EZH2 activity
can be uninhibited to maintain a repressed transcriptional
state without amplification or overexpression. These tumors
may therefore present with inherently increased EZH2
activity that can be pharmacologically targeted by an EZH2
inhibitor. EZH2 inhibitor can also be beneficial in tumors
with wild-type KDM6A and SWI/SNF complex where
increased EZH2 activity occurs through post-translational
modifications or other genetic alterations [44–46]. Post-
translational modifications that enhance EZH2 activity
include USP21-mediated de-ubiquitination [44] and JAK3-
mediated phosphorylation [45, 46]. Genetic alterations that
frequently occur in bladder tumors, for example, Rb1 loss
and c-myc amplification, also drive EZH2 expression and
activity [47, 48]. Therefore, patients who can potentially
benefit from EZH2 inhibition would include those whose
bladder tumors possess KDM6A and SWI/SNF mutations,
Rb1/c-myc alterations and post-translational modifications
of EZH2.
In our studies, EZH2 inhibition in HT1376 and T24
bladder cancer cells with KDM6A and/or SWI/SNF family
member mutations increased levels of transcripts associated
with NK cell activity. NK cells are important inhibitors of
tumor development and progression [49, 50]. For example,
TRAMP mice deficient in NKG2D/KLRK1, an NK cell
receptor, develop more aggressive prostate cancer than their
wild-type counterparts [51]. NK cell infiltration is capable
of driving tumor cell lysis [37, 52], which is evident by
greater TUNEL staining in EZH2 inhibitor-treated HT1376
xenografts. Enhanced NK cell infiltration in tumors can also
drive differentiation of pluripotent cells to sensitize these
cells to chemotherapy [36, 42].
Although the exact mechanism of epigenetic regulation
of NK cell maturity and activity is not fully understood,
EZH2 and KDM6A are known to regulate NK cell survival
and activity in mice without any tumors [53, 54]. Non-
tumor bearing mice with conditional EZH2 loss in hema-
topoietic stem and progenitor cells or those treated with
EZH2 inhibitors show enhanced cell lineage commitment,
survival and number of mature NK cells [54]. Pharmaco-
logical inhibition and knockdown of KDM6A reduces NK
cell proliferation and IFN-γ production, a primary down-
stream NK cell target [53]. In our studies, IFN-γ transcript
had the highest fold change in EZH2 inhibitor-treated
Fig. 4 EZH2 inhibition alone and in combination with cisplatin
reduces cell proliferation and increases cell death in HT1376 xeno-
grafts. a, b Representative H and E images showed no difference in
tumor morphology between the different treatments. EZH2 expression
was not altered between the treatment groups with a slight increase in
combination-treated tumors; however, H3K27me3 levels were lower
in the EPZ011989 and combination groups. Ki67, a proliferation
marker, was reduced in EPZ011989 and combination groups com-
pared to vehicle and cisplatin-treated tumors. TUNEL staining, an
apoptosis marker was higher in all treatment groups compared with
vehicle. Error bars represent standard error of means of all the mice in
each group. One-way ANOVA model with pairwise comparisons
made as appropriate were performed to test differences between single
and combination treatments. *p < 0.05, **p < 0.01, ***p < 0.001, tri-
angle indicates significant difference as compared to vehicle, hash
indicates significant difference between the EPZ011989 and cisplatin
alone treatments
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HT1376 xenografts compared to vehicle-treated xenografts.
IFN-γ has a crucial role in anti-tumor activity through
immunological stimulation of macrophages and NK cells
that drive tumor cell apoptosis [55]. Our data suggest that
EZH2 inhibition in the context of KDM6A and/or SWI/SNF
mutations increase NK cell activity that mediates IFN-γ
release to cause tumor cell death. Epigenetic modifications
other than histone methylation can also enhance NK cell-
mediated tumor cell killing. AML cells pre-treated with
Decitabine, a DNA hypomethylating agent, display
increased susceptibility to NK cell-mediated killing in leu-
kemic cell lines, xenografts and patient-derived cells [56].
DNA hypomethylation augments NK cell-mediated lysis by
increasing NKG2D-ligand expression that allows recogni-
tion of tumor AML cells by NKG2D receptor (encoded by
Killer Cell Lectin Like Receptor K1, KLRK1) on NK cells
[57]. In our studies, EPZ011989 and combination treat-
ments amplified transcript levels of genes including CD86,
MIP-1α, CD3D, as well as CD56 and NCR1 protein levels
that are indicative of active NK cells. This increase in NK
cell activity is associated with greater tumor cell death as
measured by TUNEL staining. Overall, these findings
suggest to us that NK cell-mediated tumor cell killing may
be partially response for anti-tumor activity observed with
EZH2 inhibition alone and in combination with cisplatin in
bladder cancer xenografts in nude mice.
Athymic nude mice have a limited immune cell com-
position that includes NK and B-cells but not T cells. It is
possible that EZH2 inhibition in either immune-competent
mice or human microenvironments, affects other compo-
nents of the immune system in addition to NK cells. The
cross talk between a fully developed immune system in an
immune-competent host and its response to EZH2 inhibi-
tion in tumor cells remain to be fully elucidated. EZH2
inhibition in the HT1376 xenografts also increases mRNA
of PD-L1. Others have shown that EZH2 inactivation can
potentially synergize with checkpoint-based immunother-
apy including anti-CTLA4 and PD-L1 in preclinical models
of melanoma and ovarian cancer [58, 59]. It will be fasci-
nating to study if EZH2 inhibition can augment PD-L1-
based immunotherapy, an FDA approved drug for treating
metastatic bladder cancer.
Cisplatin-based chemotherapy is the FDA-approved
frontline treatment for MIBC. Therefore, it is likely that
clinical testing of EZH2 inhibitors will involve patients that
are pre-treated with cisplatin. We show that cisplatin raised
H3K27me3 levels, an indication of increased EZH2 activity
in vitro. Another study shows that chemo-resistant tumors
from bladder cancer patients maintain or overexpress EZH2
protein levels after chemotherapy compared to patients who
are chemo-sensitive [60]. Acquired chemo-resistance in
cancer cells [40] is also associated with EZH2 over-
expression that enriches for cells with stem cell-like features
[61, 62]. Reducing the population of cells with pluripotent
features can potentially augment chemotherapy [63, 64]. It
has also been shown that NK cells can drive differentiation
of tumor cells which augment cisplatin therapy [36, 42].
NK cells can also increase cytotoxicity of colon cancer
stem-like-cells pre-treated with 5-fluorouracil or oxaliplatin-
based chemotherapy [37]. These authors further investi-
gated the efficacy of adoptive NK cell therapy in
combination with chemotherapy in comparison to che-
motherapy alone in colon cancer patients [37]. Although the
numbers are small, patients treated with combination ther-
apy had significantly higher overall and progression-free
survival compared to the chemotherapy alone arm [37]. In
our studies, EZH2 inhibition reduces expression of plur-
ipotency markers including CK5, ALDH2, and p63. Based
on these observations, our data suggest that EZH2
inhibition-mediated increase in NK cell activity has the
potential to boost response to cisplatin therapy through
increased cytotoxicity of pluripotent cells or tumor cell
differentiation. This can occur independently of KDM6A
and SWI/SNF complex mutations where prior cisplatin-
based chemotherapy can mediate increased EZH2 activity.
In MIBC where cisplatin and PD-1/PD-L1 are the only two
FDA approved treatments, EZH2 inhibition represents an
additional therapeutic option that needs to be fully explored.
Fig. 5 EZH2 inhibition is associated with NK cell activation. a Gene
set enrichment analysis shows that EZH2 inhibition alone or in com-
bination with cisplatin is associated with increased in IFN-γ signaling.
qPCR analysis showed that NK cell activity associated transcripts
IFN-γ, MIP-1α, CD3D, CYTH1, CD86, ICAM1, and ICAM2 were
significantly upregulated in the combination treatment as compared to
cisplatin alone treatment. Error bars represent standard error of means
of all the mice in each group. One-way ANOVA model with pairwise
comparisons made as appropriate were performed to test differences
between single and combination treatments. *p < 0.05, **p < 0.01,
triangle indicates significant difference as compared to vehicle, hash
indicates significant difference between the EPZ011989 and cisplatin
alone treatments. b, c CD56, an NK cell-associated marker is sig-
nificantly higher in combination-treated tumors compared to single
agent and vehicle-treated mice. NCR1, Natural Cytotoxic triggering
Receptor 1, that mediates tumor cell lysis is significantly increased in
the EPZ011989 and combination-treated groups compared to vehicle
and cisplatin-treated groups. Orange arrows indicate infiltrating cells
and black arrows point to tumor cells. Error bars represent standard
error of means of Image J quantitation in all the mice in each group.
One-way ANOVA model with pairwise comparisons made as appro-
priate were performed to test differences between single and combi-
nation treatments. *p < 0.05, **p < 0.01, triangle indicates significant
difference as compared to vehicle, hash indicates significant difference
between the EPZ011989 and cisplatin alone treatments. d RNA-
sequencing of a 66 tumors revealed significant alterations in gene
expression of a subset of ligands and receptors that are involved in the
activation of natural killer (NK) cells. e z-scores of NK related tran-
scripts are higher in tumors with no mutations compared to tumors
with KDM6A and/or SWI/SNF mutations
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Fig. 6 EZH2 inhibition-
mediated NK cell activation
reprograms bladder tumor cells
by reducing expression of
markers associated with
pluripotent potential.
a, b Markers of pluripotency in
bladder cancer, CK5, ALDH2,
and p63, were stained
heterogeneously in all tumors.
CK5 expression was
significantly reduced and
ALDH2 was reduced in
EPZ011989 and combination-
treated tumors compared with
vehicle and cisplatin-treated
tumors. p63 expression was
significantly higher in cisplatin-
treated tumors compared to
vehicle group. Orange arrows
indicate infiltrating cells and
white arrows point to tumor
cells. c RNA-sequencing
analysis of Roswell Park
muscle-invasive bladder tumors
reveal significant upregulation
of markers of cells with
pluripotency potential, with the
exception of ALDH2, compared
to non-tumor tissues.
d Pluripotency-associated
markers were significantly lower
in tumors with KDM6A
mutation compared to all the
mutation subtypes. e EZH2-
mediated H3K27me3 deposition
on histones is opposed by wild-
type KDM6A and SWI/SNF
complex. Tumor cells exhibit
greater pluripotency potential
and decreased NK cell activity
when KDM6A and SWI/SNF
loss of function mutations are
unable to counteract EZH2
activity. EZH2 inhibition in this
context increases NK cell
activity measured by IFN-γ that
mediates decrease in CK5 and
ALDH2 that are pluripotency-
associated markers. Greater NK
cell activity and reduced
pluripotency further augments
cisplatin-based chemotherapy in
muscle-invasive bladder cancer
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